Barbara Krebs-Pohl, Ph.D.

Dr. Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide.

In her role as Chief Integration Officer, she is working from Cambridge, Mass. to lead the integration of Constellation and build the strategic roadmap for the combined companies as an emerging leader in hematology-oncology.

Since joining MorphoSys in 1998, Dr. Krebs-Pohl has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the “Astra Zeneca Business Development Executive of the Year 2013” Award.

Prior to joining MorphoSys, Dr. Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.